Show simple item record

dc.contributor.authorLozada, Issiah
dc.contributor.authorHuang, Bin
dc.contributor.authorStilgenbauer, Morgan
dc.contributor.authorBeach, Travis
dc.contributor.authorQiu, Zihan
dc.contributor.authorZheng, Yaorong
dc.contributor.authorHerbert, David E
dc.date.accessioned2021-10-22T17:54:17Z
dc.date.available2021-10-22T17:54:17Z
dc.date.issued2020-04-20
dc.date.submitted2021-10-15T21:05:26Zen_US
dc.identifier.citationDalton Transactions, 2020, 49, 6557-6560en_US
dc.identifier.urihttp://hdl.handle.net/1993/36060
dc.description.abstractPhenanthriplatin is a leading preclinical anticancer Pt complex distinguished by a phenanthridine ligand that facilitates DNA-targeted covalent binding via intercalation. We report here that Pt(II) complexes incorporating phenanthridine into a chelating, multidentate ligand scaffold exhibit a superior in vitro therapeutic index compared with phenanthriplatin and cisplatin.en_US
dc.description.sponsorshipNatural Sciences and Engineering Research Council of Canada (RGPIN-2014-03733)en_US
dc.language.isoengen_US
dc.publisherRoyal Society of Chemistryen_US
dc.rightsopen accessen_US
dc.subjectchemotherapeuticsen_US
dc.subjectCoordination Chemistryen_US
dc.titleMonofunctional platinum(ii) anticancer complexes based on multidentate phenanthridine-containing ligand frameworksen_US
dc.typePreprinten_US
dc.identifier.doi10.1039/D0DT01275K
local.author.affiliationFaculty of Scienceen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record